natgillin/translations-raw huggingface dataset:
If you have ever had this type of reaction to a similar medicine, talk to your doctor before using Pergoveris. 
Če ste kadar koli že imeli takšno reakcijo na podobno zdravilo, se o tem posvetujte z zdravnikom, preden uporabite zdravilo Pergoveris.
There is evidence to suggest that hCG plays a key role in triggering OHSS and that the syndrome may be more severe and more protracted if pregnancy occurs. 
Obstajajo dokazi, da ima hCG pomembno vlogo pri sprožanju OHSS ter da bi bil sindrom hujši in dolgotrajnejši, če bi prišlo do nosečnosti.
If you are developing OHSS your doctor may not give you any hCG in this treatment cycle and you may be told not to have sex or that you should use a barrier contraceptive method for at least four days. 
Če se razvije OHSS, vam zdravnik ne sme dati hCG v tem ciklusu zdravljenja in morda vam bo povedal, da ne smete imeti spolnih odnosov ali pa morate uporabljati mehanska kontracepcijska sredstva najmanj štiri dni.
• your skin becomes fragile and easily blistered, especially skin that has been frequently exposed to sunlight 
• postaja vaša koža krhka in se hitro tvorijo mehurji zlasti na tistih delih, ki so bili pogosto izpostavljeni soncu,
Since these patients are amenorrhoeic and have low endogenous oestrogen secretion, treatment can commence at any time. 
Ker so te bolnice amenoreične in imajo nizko izločanje endogenega estrogena, se zdravljenje lahko začne kadar koli.
• Your doctor or nurse will show you how to prepare and inject this medicine. 
• Vaš zdravnik ali medicinska sestra vam bo pokazala, kako pripraviti in injicirati zdravilo.
Store in refrigerator (2°C- 8°C). 
Shranjujte v hladilniku (2 °C - 8 °C).
Both belong to the family of hormones called “gonadotropins”, which are involved in reproduction and fertility. 
Obe spadata v skupino hormonov, ki se imenujejo „gonadotropini“ in sodelujejo pri razmnoževanju in plodnosti.
Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion. 
Poškodbe jajčnika zaradi slabše prekrvavitve se lahko omeji z zgodnjo diagnozo in takojšnjo detorzijo.
The lowest effective dose in relation to the treatment objective should be used in women. 
Pri ženskah se mora uporabiti najmanjši še učinkoviti odmerek glede na cilj zdravljenja.
Talk to your doctor before you start your treatment.If you or any member of your family have porphyria (an inability to breakdown porphyrins that may be passed on from parents to children). 
Pred začetkom zdravljenja povejte zdravniku, če imate vi ali kdo v družini porfirijo (nezmožnost razgradnje porfirinov, ki se lahko prenaša s staršev na otroke).
• When the pen is empty, ask your pharmacist how to dispose of it. 
• Ko je peresnik prazen, vprašajte farmacevta, kako ga zavreči.
In these patients, Pergoveris may increase the risk of an acute attack. 
Pri teh bolnicah lahko zdravilo Pergoveris poveča tveganje za akutni napad.
6.6 Special precautions for disposal and other handling For immediate and single use following first opening and reconstitution. 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Za takojšnjo in enkratno uporabo po prvem odprtju in rekonstituciji.
Dispose of all used items. 
Vse uporabljene predmete odstranite.
The patient should be hospitalised and specific therapy for OHSS started. 
Bolnico se mora sprejeti v bolnišnico in začeti s specifičnim zdravljenjem OHSS.
Verify you have given a complete injection. 
Preverite, ali ste dali celo injekcijo.
In case of above events your doctor may recommend that you stop treatment. 
V zgoraj naštetih primerih vam lahko zdravnik priporoči prekinitev zdravljenja.
It is not yet established whether or not treatment with gonadotropins increases the risk of these tumours in infertile women. 
Ni pa še ugotovljeno, ali zdravljenje z gonadotropini povečuje tveganje teh tumorjev pri neplodnih ženskah.
You can turn the dose knob backwards if you turn it past 25 (Fig. 5). 
Gumb za nastavitev odmerka lahko obrnete nazaj, če ga obrnete preko 25 (sl. 5).
Window will turn back to 0. 
se vrne na 0.
When you do this, please carefully read and follow the instructions hereafter called “How to prepare and use the Pergoveris powder and solvent”. 
Ko to počnete, skrbno preberite in upoštevajte napotke v nadaljevanju teh navodil, imenovane „Priprava in uporaba zdravila Pergoveris prašek in vehikel“.
How to prepare and use the Pergoveris powder and solvent Before starting the preparation, please read these instructions the whole way through first: Give yourself the injection at the same time each day. 
Priprava in uporaba zdravila Pergoveris prašek in vehikel Preden začnete s pripravo, najprej v celoti preberite ta navodila: Zdravilo si injicirajte vsak dan ob istem času.
• Complications of OHSS such as twisting of ovaries or blood clotting occur rarely (may affect up to 1 in 1,000 people). 
• Zapleti OHSS, kot je torzija jajčnikov ali nastajanje krvnih strdkov, se pojavijo redko (pojavijo se lahko pri do 1 od 1.000 bolnic).
• If they are satisfied that you can administer Pergoveris safely, you can then prepare and inject the medicine yourself at home. 
• Če bodo menili, da lahko zdravilo Pergoveris uporabljate na varen način, si lahko zdravilo pripravite in injicirate sami doma.
Tumours of sex organs 
Tumorji na spolnih organih
Gonadotrophin therapy requires a certain time commitment by physicians and supportive health care professionals, as well as the availability of appropriate monitoring facilities. 
Zdravljenje z gonadotropini zahteva od zdravnika in drugega zdravstvenega osebja določen čas, kakor tudi razpoložljivost ustrezne opreme za nadzorovanje zdravljenja.
In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thromboembolic events, such as personal or family history, thrombophilia or severe obesity (body mass index > 30 kg/m2), treatment with gonadotrophins may further increase the risk. 
Pri ženskah z nedavno ali trenutno prisotno trombembolično boleznijo ali ženskah s splošno znanimi dejavniki tveganja za trombembolične dogodke, kot so osebna ali družinska anamneza, trombofilija ali huda debelost (indeks telesne mase > 30 kg/m2) lahko zdravljenje z gonadotropini še poveča tveganje.
• malformations of sexual organs incompatible with pregnancy 
• malformaciji spolnih organov, ki niso združljive z nosečnostjo
Elimination Total clearance is around 2 L/h, and less than 5% of the dose is excreted in the urine. 
Izločanje Celokupni očistek je približno 2 l/h in manj kot 5 % odmerka se izloči z urinom.
You can reduce the risk of multiple pregnancy by using the right dose of Pergoveris at the right times. 
Tveganje večplodne nosečnosti lahko zmanjšate tako, da ob pravem času uporabite pravi odmerek zdravila Pergoveris.
In particular, patients should be evaluated for hypothyroidism, adrenocortical deficiency, hyperprolactinemia and appropriate specific treatment should be given. 
Bolnike je treba še posebej pregledati na hipotiroidizem, adrenokortikalno insuficienco, hiperprolaktinemijo ter jih ustrezno specifično zdraviti.
Do not share the pen and/or needles with another person, because doing so can cause an infection. 
Ne delite peresnika in/ali injekcijskih igel z drugo osebo, saj lahko to povzroči okužbo.
Verify the expiration date on the pen label (Fig. 2). 
Preverite datum izteka roka uporabnosti na nalepki peresnika (sl. 2).
Talk to your doctor before using Pergoveris if you or a member of your family have ever had blood clots in the leg or in the lung, or a heart attack or stroke. 
Pred začetkom uporabe zdravila Pergoveris se posvetujte z zdravnikom, če ste vi ali kak član vaše družine kdaj imeli krvne strdke v nogi ali pljučih ali če ste doživeli srčni napad ali kap.
In these women, the benefits of gonadotrophin administration need to be weighed against the risks. 
Pri teh ženskah je treba pretehtati koristi uporabe gonadotropinov glede na tveganje.
Ovarian torsion has been reported after treatment with other gonadotropins. 
O torziji jajčnika so poročali po zdravljenju z ostalimi gonadotropini.
The effects of an overdose of Pergoveris are unknown. 
Učinki prevelikega odmerka zdravila Pergoveris niso znani.
DO NOT discard it. 
NE zavrzite ga.
In this case, the follitropin alfa dose is usually increased every 7 or every 14 days by 37.5 to 75 IU. 
V tem primeru se odmerek zdravila folitropin alfa navadno poveča vsakih 7 ali 14 dni za 37,5 do 75 i.e.
Blood clotting problems (thromboembolic events) 
Težave s strjevanjem krvi (trombembolični dogodki)
If you forget to use Pergoveris Do not use a double dose to make up for a forgotten dose. 
Če ste pozabili uporabiti zdravilo Pergoveris Ne uporabite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
The pH of the reconstituted solution is 6.5-7.5. 
Rekonstitucija pH rekonstituirane raztopine je 6,5 - 7,5.
Following subcutaneous administration, the absolute bioavailability is about 70%. 
Po subkutani aplikaciji je absolutna biološka uporabnost 70 %.
Allergic reactions such as rash, red skin, hives, swelling of your face with difficulty breathing can sometimes be serious. 
Alergijske reakcije, kot so izpuščaji, pordela koža, koprivnica, oteklina obraza z oteženim dihanjem, so včasih lahko resne.
Use the treatment diary to record the amount injected. 
Dnevnik zdravljenja uporabljajte za beleženje injicirane količine.
Pepare a clean area and a flat surface, such as a table or countertop, in a well-lit area. 
3.2.Pripravite čisto območje in ravno površino, na primer mizo ali kuhinjski pult, v dobro osvetljenem prostoru.
• if you have a brain tumour (in your hypothalamus or pituitary gland) 
• če imate možganski tumor (v hipotalamusu ali hipofizi),
• if you are allergic to follicle stimulating hormone (FSH), luteinising hormone (LH) or any of the other ingredients of this medicine (listed in section 6) 
• če ste alergični na folikle stimulirajoči hormon (FSH), luteinizirajoči hormon (LH) ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
6.6 Special precautions for disposal and other handling Only clear solution without particles should be used. 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Uporabljajte samo bistro raztopino brez delcev.
When you get the desired response, you will be given a single injection of human chorionic gonadotropin (hCG) 24 to 48 hours after your last Pergoveris injection. 
Ko dosežete želeni odziv, boste dobili eno samo injekcijo humanega horionskega gonadotropina (hCG) 24 do 48 ur po zadnji injekciji zdravila Pergoveris.
Pergoveris is indicated for use in infertility (see section 4.1). 
Zdravilo Pergoveris je indicirano za uporabo pri neplodnosti (glejte poglavje 4.1).
Usually, OHSS resolves spontaneously with the onset of menses. 
OHSS običajno spontano izzveni ob nastopu menstruacije.
Monitoring of stimulation cycles by ultrasound scans as well as oestradiol measurements are recommended to early identify risk factors. 
Priporočeno je nadzorovanje ciklov stimulacije z ultrazvokom ter meritve estradiola za zgodnje odkrivanje dejavnikov tveganja.
In this case, your doctor will give you a lower follitropin alfa dose in the following cycle. 
V tem primeru vam bo zdravnik v naslednjem ciklu dal manjši odmerek folitropina alfa.
• you have stomach, arm or leg pain. 
• imate bolečine v trebuhu, rokah ali nogah.
• Serious blood clotting problems (thromboembolic events) usually with severe OHSS are found very rarely. 
• Resni zapleti zaradi krvnih strdkov (trombembolični dogodki), običajno pri hudi OHSS, so zelo redki.
• The pen comes in 3 different multi-dose presentations: 
• Peresnik je na voljo v 3 različnih večodmernih oblikah:
• Record the treatment day number (column 1), date (column 2), time of your injection (column 
• Zabeležite številko dneva zdravljenja (stolpec 1), datum (stolpec 2), čas injiciranja
• It comes as a powder and liquid, which you need to mix together and then use straight away. 
• Zdravilo je v obliki praška in tekočine, ki ju zmešate in takoj uporabite.
Safety, efficacy, and pharmacokinetics of this medicinal product in patients with renal or hepatic impairment have not been established. 
Varnost, učinkovitost in farmakokinetika tega zdravila pri bolnikih z okvaro ledvic ali jeter niso bile dokazane.
• if you have unexplained vaginal bleeding 
• če imate nepojasnjeno krvavitev iz nožnice,
Wipe the skin with an alcohol swab. 
Kožo obrišite z alkoholno blazinico.
Warning: If the Dose Feedback Window shows a number higher than 0, the Pergoveris pre-filled pen is empty and you have not received your full prescribed dose. 
Opozorilo: Če je številka v okencu za prikaz odmerka večja od 0, to pomeni, da je Pergoveris napolnjen injekcijski peresnik prazen in da niste prejeli celotnega predpisanega odmerka.
• hypersensitivity to the active substances or to any of the excipients listed in section 6.1 
• s preobčutljivostjo na učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1;
To minimise the risk of multiple pregnancy, careful monitoring of ovarian response is recommended. 
Za zmanjšanje tveganja večplodne nosečnosti, se priporoča skrbno spremljanje ovarijskega odziva.
Following subcutaneous administration, the absolute bioavailability is approximately 60%; the terminal half-life is slightly prolonged. 
Po subkutani aplikaciji je absolutna biološka uporabnost okoli 60 %; končni razpolovni čas je rahlo podaljšan.
Driving and using machines It is not expected that this medicine will affect your ability to drive or use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Ne pričakuje se, da bi zdravilo vplivalo na sposobnost vožnje ali upravljanja strojev.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI BIOLOŠKE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
You may be at a higher risk of serious blood clots or existing clots might become worse with Pergoveris treatment. 
Morda je pri vas tveganje za resne krvne strdke večje ali se obstoječi strdki lahko poslabšajo ob jemanju zdravila Pergoveris.
A comparative clinical study between the freeze-dried and the liquid formulation showed bioequivalence between the two formulations. 
Primerjalna klinična študija med liofiliziranim in tekočim pripravkom je pokazala bioekvivalenco med tema dvema pripravkoma.
Warning: Check that the Dose Feedback Window displays your complete prescribed dose before you move on to the next step. 
Opozorilo: Preverite, ali okno za nastavitev odmerka prikazuje celotni predpisani odmerek, preden nadaljujete z naslednjim korakom.
• FSH stimulates the production of eggs 
• FSH stimulira nastanek jajčec
If severe OHSS occurs, gonadotropin treatment should be stopped if still ongoing. 
Če se pojavi hud OHSS, se mora ukiniti zdravljenje z gonadotropinom, v kolikor še traja.
Caution: Do not attach the needle too tightly; the needle could be difficult to remove after the injection. 
Igle ne pritrdite preveč tesno; morda jo bo po injiciranju težko odstraniti.
• if you have large ovaries or sacs of fluid within your ovaries (ovarian cysts) of unknown origin 
• če imate velike jajčnike ali vrečke tekočine znotraj jajčnikov (ciste jajčnika) neznanega izvora,
• Remove any air bubbles: If you see air bubbles in the syringe, hold the syringe with the needle pointing upwards and gently flick the syringe until all the air collects at the top. 
• Odstranite morebitne zračne mehurčke: če vidite mehurčke zraka v brizgi, jo držite tako, da igla gleda navzgor in nežno krcajte (lahno udarjajte s prstom) brizgo, da se ves zrak zbere na vrhu.
Very rare (may affect up to 1 in 10,000 people): • Your asthma may get worse. 
Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov) • poslabšanje astme.
Therefore, if signs of OHSS occur such as serum oestradiol level > 5,500 pg/mL or > 20,200 pmol/L and/or ≥ 40 follicles in total, it is recommended that hCG be withheld and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4 days. 
Zato je v primeru pojava znakov OHSS, kot so ravni estradiola v serumu > 5.500 pg/ml ali > 20.200 pmol/l in/ali skupno ≥ 40 foliklov, priporočljivo, da se opusti dajanje hCG in se bolnici svetuje, da se vzdrži spolnih odnosov ali uporablja mehanska kontracepcijska sredstva najmanj 4 dni.
Pergoveris treatment seldom causes severe OHSS. 
Zdravljenje z zdravilom Pergoveris redko povzroči hud OHSS.
b. Verify a complete injection. 
b. Preveriti popolnost injiciranja.
This becomes more likely if the medicine that is used for final follicular maturation (containing human chorionic gonadotrophin, hCG) is administered (see in section 3. under “How much to use” for details). 
To je bolj verjetno, če se daje zdravilo, ki se uporablja za spodbuditev končnega folikularnega zorenja (ki vsebuje humani horionski gonadotropin - hCG) (za več podrobnosti glejte poglavje 3 „Koliko zdravila uporabiti“).
This side effect is very rare. 
Ta neželeni učinek je zelo redek.
Your doctor will tell you how many IUs of follitropin alfa to inject each day. 
Zdravnik vam bo povedal, koliko i.e. folitropina alfa si morate vsak dan injicirati.
The active substances in Pergoveris are copies of the natural hormones FSH and LH. 
Učinkovini v zdravilu Pergoveris sta kopiji naravnih hormonov FSH in LH.
NOTE: Using your treatment diary to record your daily injection(s) allows you to verify that you received the full prescribed dose every day. 
OPOMBA: Uporaba dnevnika zdravljenja za beleženje dnevnih injiciranj omogoča preverjanje, da ste vsak dan prejeli celotni predpisani odmerek.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 25 June 2007 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 25. junij 2007 Datum zadnjega podaljšanja: 8. maj 2017
In rare cases this can also happen independently of OHSS (see in section 2. under “Blood clotting problems (thromboembolic events)”). 
V redkih primerih lahko pride do tega neodvisno od OHSS (glejte poglavje 2 pod „Težave s strjevanjem krvi (trombembolični dogodki)“).
Manufacturer Merck Serono S.p.A, Via delle Magnolie 15 (Zona industriale), I-70026 Modugno (Bari), Italy 
Izdelovalec Merck Serono S.p.A, Via delle Magnolie 15 (Zona industriale), I-70026 Modugno (Bari), Italija
• After a minimum of 5 seconds, pull the needle out of the skin while keeping the dose setting knob pressed down (Fig. 11). 
• Po vsaj 5 sekundah izvlecite injekcijsko iglo iz kože in še vedno držite pritisnjen gumb za nastavitev odmerka (sl. 11).
Treatment with Pergoveris should be initiated under the supervision of a physician experienced in the treatment of fertility problems. 
Zdravljenje z zdravilom Pergoveris se mora začeti pod nadzorom zdravnika, ki je izkušen v zdravljenju težav s plodnostjo.
* The numbers on the Dose Feedback Window and reservoir holder represent the number of International Units (IU) of medication. 
* Številke na oknu za prikaz odmerka in prostoru za tekočino predstavljajo število mednarodnih enot (i.e.) zdravila.
Pergoveris has no or negligible influence on the ability to drive and use machines. 
Zdravilo Pergoveris nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
• It is important that your hands and the items you use be as clean as possible 
• Pomembno je, da so vaše roke in predmeti, ki jih uporabljate, kolikor je le mogoče čisti • Primerna površina je čista miza ali kuhinjska površina
• one sharps container for safe disposal of glass and needles 
• posoda za ostre predmete za varno odlaganje stekla in igel
If you get lower abdominal pain, gain any weight rapidly, feel sick or are vomiting or if you have difficulty in breathing, talk to your doctor straight away. 
Če se pojavijo bolečine v spodnjem delu trebuha, če hitro pridobite telesno maso, če vam je slabo ali bruhate ali imate težave z dihanjem, se takoj pogovorite z zdravnikom.
• Alcohol swabs (not included in the pack) 
•alkoholne blazinice (niso vključene v pakiranju),
Patients with porphyria or a family history of porphyria should be closely monitored during treatment with Pergoveris. 
Bolnice s porfirijo ali s porfirijo v družinski anamnezi, morajo biti med zdravljenjem z zdravilom Pergoveris skrbno nadzorovane.
In women, safe and effective use of Pergoveris calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis. 
Pri ženskah je za varno in učinkovito uporabo zdravila Pergoveris potrebno redno nadzorovanje odziva jajčnikov z ultrazvokom ali po možnosti z ultrazvokom v kombinaciji z merjenjem serumskih ravni estradiola.
Alternatively, intrauterine insemination (IUI) may be performed. 
Alternativno, se lahko izvede intrauterina oploditev (IUI - Intrauterine Insemination).
• ovarian enlargement or ovarian cyst unrelated to polycystic ovarian disease and of unknown origin 
• s povečanjem jajčnikov ali cisto jajčnika, ki ni povezana s policistično boleznijo ovarijev in je neznanega izvora;
It is for use in adult women (18 years old or above) who have low levels (severe deficiency) of “follicle stimulating hormone” (FSH) and “luteinising hormone” (LH). 
Zdravilo je namenjeno odraslim ženskam (starim 18 let ali več) z nizkimi ravnmi (hudim pomanjkanjem) „folikel stimulirajočega horona“ (FSH) in „luteinizirajočega hormona“ (LH).
• The numbers displayed in the Dose Feedback Window help you to: 
• Številke, prikazane v okencu za prikaz odmerka, vam bodo pomagale:
Pergoveris should not be administered as a mixture with other medicinal products, in the same injection, except follitropin alfa for which studies have shown that co-administration does not significantly alter the activity, stability, pharmacokinetic nor pharmacodynamic properties of the active substances. 
Zdravila Pergoveris se ne sme dajati v obliki mešanice z drugimi zdravili v isti injekcijski brizgi, razen s folitropinom alfa, za katerega so študije pokazale, da njegovo sočasno dajanje ne spremeni pomembno učinka, stabilnosti, farmakokinetičnih ali farmakodinamičnih lastnosti učinkovin.
Before starting treatment, the couple's infertility should be assessed as appropriate and putative contraindications for pregnancy evaluated. 
Pred začetkom zdravljenja se mora oceniti neplodnost para kot primerno ter ovrednotiti domnevne kontraindikacije za nosečnost.
Paediatric population There is no relevant use of this medicinal product in the paediatric population. 
Pediatrična populacija To zdravilo ni namenjeno za uporabo pri pediatrični populaciji.
THEN 
POTEM
Children and adolescents Pergoveris is not for use in children and adolescents below 18 years old. 
Otroci in mladostniki Otroci in mladostniki do 18 leta starosti zdravila Pergoveris ne smejo uporabljati.
This side effect is uncommon (may affect up to 1 in 100 people). 
Ta neželeni učinek je občasen (pojavi se lahko pri do 1 od 100 bolnic).
In case you are not ovulating and if the recommended dose and schedule of administration are adhered to, the occurrence of severe OHSS is less likely. 
V primeru, da ne ovulirate in upoštevate priporočeni odmerek zdravljenja in shemo dajanja zdravila, je manj verjetno, da bi se pojavil OHSS.
The steady state volume of distribution is around 10-14 L. Lutropin alfa shows linear pharmacokinetics, as assessed by AUC which is directly proportional to the dose administered. 
Volumen porazdelitve v stanju dinamičnega ravnovesja je približno 10-14 l. Lutropin alfa kaže linearne farmakokinetične lastnosti, kot so ocenili z AUC, ki je direktno sorazmerna danemu odmerku.
• Pick up your syringe and slowly inject the contents of the syringe into the vial of powder. 
• Primite brizgo in počasi injicirajte vsebino brizge v vialo s praškom.
Pergoveris is contraindicated in patients with: 
Zdravilo Pergoveris je kontraindicirano pri bolnicah:
• Record this remaining dose in the “Amount Set to Inject” section in the next row (column 6). 
• Zabeležite preostali odmerek v poglavje "Količina, ki jo nastavite za injiciranje" v naslednji vrstici (stolpec 6).
Pregnancy and breast-feeding Do not use Pergoveris if you are pregnant or breast-feeding. 
Nosečnost in dojenje Ne uporabljajte zdravila Pergoveris, če ste noseči ali če dojite.